Novo Nordisk’s (NVO) GLP-1 weight loss drugs, Ozempic and Wegovy, will be targeted in the next round of Medicare price negotiations in 2027, along with 13 other medications.
Seana Smith and Brad Smith break down the details on Morning Brief.
The last round of the Inflation Reduction Act (IRA) negotiations gave Medicare an average 22% price reduction for the drugs on this list. With $41 billion in annual Medicare spending on these drugs, the implications for healthcare costs — especially obesity treatments — are massive. However, questions loom around regulatory decisions under a new Trump administration, adding complexity to future outcomes.
To watch more expert insights and analysis on the latest market action, check out more Morning Brief here.
This post was written by Josh Lynch
